About CanSense
Delivering one simple solution for 1.9 million problems
A global challenge
Bowel cancer, also referred to as colorectal cancer, stands as the third most prevalent cancer worldwide and the second leading cause of cancer-related deaths globally. Annually, it leads to approximately 1.9 million new cases and 930,000 deaths. Within Europe, bowel cancer ranks as the second most common cancer, with over 470,000 new cases each year. Incidence rates remain stubbornly high in developed nations and are rapidly rising in developing countries. However, it is widely recognised that early detection plays the most pivotal role in saving lives.
CanSense is at the forefront of transforming bowel cancer diagnosis with a fast, cost-effective and scalable test that leverages artificial intelligence-based modeling (AI). This innovative approach combines high-throughput spectroscopy with proprietary AI technology to create a game-changing, non-invasive blood test focused on accurate early detection and patient acceptability. By reducing the need for invasive colonoscopies and alleviating the financial burden on healthcare providers, this test aims to significantly improve patient outcomes and reduce mortality rates
Cansense is bringing to market an innovation to meet this global demand for early diagnosis via an accurate, cost-effective and scalable solution.
Acknowledging the urgency for change, CanSense is committed to equipping clinicians with a simple tool capable of the earliest of detection for best patient outcomes. Our cutting-edge technology revolutionises the diagnostic journey, mitigating patient anxiety from prolonged waiting times and invasive procedures, helping clinicians make the right decision for the right patient – at the right time. Improving the recruitment of patients by pharmaceutical companies for clinical trials and enhancing the monitoring of patient remission to more effectively assess the progress of new drug therapies.
With only 15% of colorectal cancers detected early, the need for such groundbreaking solutions is clear. CanSense is dedicated to reshaping the landscape of bowel cancer detection, ultimately improving survival rates and saving lives.
Innovation in science and medicine
CanSense is poised to deliver a tool to detect bowel cancer early, saving lives and reducing distress on patients and families. CanSense is establishing itself as a leading diagnostic company, providing an innovation to laboratories to detect both accurately and in its earliest stages, the presence of colorectal cancers directly benefitting both patients, doctors and healthcare providers.
Our blood test is designed to offer significant support to pharmaceutical developments in new and emerging drug therapies.
It aims to help dramatically reduce the mortality rate of colorectal cancer and reduce the burden to healthcare providers of unnecessary colonoscopies. The economic costs associated with negative colonoscopy procedures is significant and is estimated to be at least $4.2B globally.
For example, the CanSense-CRC test saving is estimated to be around £250 million per annum for the NHS alone in a reduction of colonoscopies and further savings can be made in a reduction from late-stage cancer costs.
The solution
Our blood test can be used to inform healthcare professionals as to the necessity of further colonoscopy investigation. From the anxious symptomatic patient’s perspective this triage-type process for bowel cancer offers great benefit and represents excellent news. The result will rapidly and accurately identify the patients requiring urgent priority treatment. For those patients given the all clear, it removes the need for a colonoscopy and quickly alleviates their anxiety.
The test can be applied to support clinical trials which are focused on resectable high-risk colorectal cancer. In that regard the purpose is to identify those most likely to benefit from the new treatment and support the regulatory drug approval process.
CanSense works in partnership with patients, business, healthcare and our academic partners to optimise the performance, development and opportunities for our diagnostic. Our current clinical trials are motivated by these factors.